BioStock: Analysts see high value in Iconovo’s business

As Iconovo solidifies its product development and takes aim at a global market, a new analysis by Danske Bank indicates that the inhaler development company represents a significant market opportunity, thanks to its scalable business model in particular. The analysis values the company at 78-101 SEK per share – at least a 32 per cent increase from the current share price. 

Read the full article at biostock.se:

https://www.biostock.se/en/analysts-see-high-value-in-iconovos-business/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se